Showing results (61-70 of 86) with videos related to
Sort By:
Pageof 9
Scientific Reports|November 11, 2023
Investigation of risk factors for metachronous recurrence in patients with early gastric adenocarcinoma by miRNA-mRNA integral profilingAriki Nagashima, Kenichiro Okimoto, Ryo Nakagawa, et al.Journal of Extracellular Vesicles|June 14, 2021
Early prediction of COVID-19 severity using extracellular vesicle COPB2Yu Fujita, Tokio Hoshina, Juntaro Matsuzaki, et al.Biochemical Pharmacology|February 27, 2025
MEGF6 knockdown ameliorates lenvatinib-induced muscle differentiation suppression and enhances the antitumor effect of lenvatinib on hepatocellular carcinomaNa Qiang, Junjie Ao, Masato Nakamura, et al.Cancer Medicine|December 9, 2025
Plexin Domain Containing 2, a Protein Specifically Expressed and Elevated in Human Pancreatic Cancer Tissue and Serum, Influences Cell Proliferation by Correlating With CortactinJunya Tsuboi, Akiko Eguchi, Hiroyuki Inoue, et al.International Journal of Molecular Sciences|October 14, 2022
Antiviral Compounds Screening Targeting HBx Protein of the Hepatitis B VirusYaojia Ma, Shingo Nakamoto, Junjie Ao, et al.Laboratory Investigation; a Journal of Technical Methods and Pathology|June 1, 2022
A diet-induced murine model for non-alcoholic fatty liver disease with obesity and insulin resistance that rapidly develops steatohepatitis and fibrosisTakafumi Sakuma, Masato Nakamura, Tetsuhiro Chiba, et al.Biochemical and Biophysical Research Communications|March 6, 2021
Acquisition of mesenchymal-like phenotypes and overproduction of angiogenic factors in lenvatinib-resistant hepatocellular carcinoma cellsJunjie Ao, Tetsuhiro Chiba, Shuhei Shibata, et al.Hepatology Research : the Official Journal of the Japan Society of Hepatology|June 29, 2024
Cytokine release syndrome following durvalumab and tremelimumab in advanced hepatocellular carcinoma: A case report with cytokine and damage-associated molecular pattern analysisTomomi Ozaki, Sae Yumita, Sadahisa Ogasawara, et al.International Immunopharmacology|March 31, 2023
Alteration of the tumor microenvironment by pharmacological inhibition of EZH2 in hepatocellular carcinomaNa Qiang, Junjie Ao, Masato Nakamura, et al.Journal of Cancer|April 15, 2021
Serum Angiopoietin 2 acts as a diagnostic and prognostic biomarker in hepatocellular carcinomaJunjie Ao, Tetsuhiro Chiba, Hiroaki Kanzaki, et al.Pageof 9